PRDX2 and colonic neoplasm: When the Hh pathway was inhibited in HT29 cells with the SMO inhibitor cyclopamine, reduced expression of stemness markers, such as CD44 and CD133, was observed (Figure 6B), suggesting that Prdx2 may promote CSC-associated properties in colon cancer via the Hh/Gli1 signaling pathway.